Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.
新兴病毒感染,包括那些由登革热病毒(DENV)和委内瑞拉马脑炎病毒(VEEV)引起的感染,构成了全球重大的健康挑战。在这里,我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物,每个化合物占据着不同的化学空间,包括3-((6-溴喹啉-4-基)氨基)酚(12)、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺(50)和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮(52),对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性,CC50值大于10 µM。此外,主导化合物被筛选用于对抗VEEV,并在低个位数微摩尔范围内展示了活性,其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力,以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。